New Guidelines: PPIs and Anti-Acidity Drugs (2023-2025)

1. The Drug Classes at a Glance

2. GERD - ASGE 2025 Guideline (PMID 39692638)

• Always start with lifestyle modifications (weight loss, head-of-bed elevation, dietary changes) before or alongside drug therapy.
• PPIs remain first-line medical management for symptomatic, confirmed GERD with predominant heartburn. Use at the lowest effective dose for the shortest duration possible.
• Upper endoscopy is indicated for alarm symptoms, multiple Barrett's esophagus risk factors, or history of sleeve gastrectomy.
• In patients with small hiatal hernias (≤2 cm, Hill grade I-II), transoral incisionless fundoplication (TIF) is suggested as an alternative to chronic PPI use.
• In patients with large hiatal hernias (>2 cm, Hill grade III-IV) and persistent GERD, surgical therapy or combined TIF (cTIF) is recommended over indefinite PPI continuation.
• The message is clear: PPIs should not default to lifelong therapy - the appropriateness of continued use must be re-evaluated regularly.

3. H. pylori Eradication - ACG 2024 Guideline (PMID 39626064)

• Bismuth quadruple therapy (BQT) x 14 days is now the preferred empiric first-line regimen when antibiotic susceptibility is unknown (replaces the older clarithromycin triple therapy as first-line).
• Rifabutin triple therapy or P-CAB dual therapy (vonoprazan + amoxicillin) x 14 days are suitable alternatives in patients without penicillin allergy.
• Clarithromycin- and levofloxacin-based regimens should only be used with confirmed antibiotic susceptibility.
• Universal post-treatment test-of-cure is now recommended for all patients.
• PPIs remain integral to all eradication regimens, but P-CABs are increasingly preferred as the acid suppressant component (see Section 5 below).

4. Stress Ulcer Prophylaxis in ICU - SCCM/ASHP 2024 Guideline (PMID 39007578)

• Stress ulcer prophylaxis (SUP) is recommended only for critically ill adults with specific risk factors: coagulopathy, shock, or chronic liver disease. Mechanical ventilation alone is no longer considered sufficient indication.
• Either PPIs or H2 blockers at low doses are acceptable for SUP - there is no strong evidence favoring one over the other.
• Enteral nutrition likely reduces gastrointestinal bleeding risk and should be initiated when feasible.
• Prophylaxis must be discontinued when the critical illness resolves or the risk factor is no longer present, and certainly before ICU transfer. This addresses the major problem of inappropriate PPI continuation after discharge.

5. P-CABs (Vonoprazan) - AGA 2024 Clinical Practice Update (PMID 39269391)

• Act faster (acid suppression within hours vs. days for PPIs)
• Not prodrugs - no need for acid activation, so food timing matters less
• Efficacy is less dependent on CYP2C19 genotype
• Potent, more consistent intragastric pH control

• Cost caveat: Even modest clinical superiority of P-CABs over double-dose PPIs may not make them cost-effective as first-line therapy at current US pricing.

6. PPI Stewardship - Indian Society of Gastroenterology 2023 (PMID 37698821)

• GERD and erosive esophagitis
• Peptic ulcer disease (H. pylori eradication; NSAID-related ulcers)
• Zollinger-Ellison syndrome
• Upper GI bleeding (acute and prevention in high-risk patients on antithrombotics)
• Eosinophilic esophagitis
• Stress ulcer prophylaxis (in high-risk ICU patients only)
• Barrett's esophagus chemoprevention

• Routine co-prescription with all antibiotics or corticosteroids (without GI risk factors)
• Non-specific abdominal pain without acid-peptic workup
• Nausea, vomiting without established acid-peptic etiology
• Prophylaxis in low-risk hospitalized patients

7. Long-Term PPI Safety Concerns and Deprescribing

• Hypomagnesemia and hypokalemia (especially >1 year)
• Vitamin B12 and iron malabsorption
• Increased risk of Clostridioides difficile infection
• Community-acquired pneumonia (modest association)
• Osteoporosis/fracture risk (particularly hip fracture in older adults)
• Rebound acid hypersecrerity upon abrupt discontinuation (2-4 weeks)
• Potential increased risk of CKD (association data, causality debated)

• Barrett's esophagus
• Severe erosive esophagitis (LA grade C/D)
• Zollinger-Ellison syndrome
• Documented recurrent GI ulcer/bleeding
• Eosinophilic esophagitis with confirmed PPI response

1. Assess whether the original indication still applies
2. If it does not, trial dose reduction or discontinuation
3. Options: dose halving, on-demand therapy, or switch to H2 blocker/antacid
4. Warn patients about rebound heartburn (2-4 weeks) and provide management strategies
5. Follow up at 4-12 weeks and reassess

• Structured programmes achieve up to 86% discontinuation success vs. historical rates of 30-60%

8. Pharmacology Notes Relevant to Prescribing

• Take PPIs 30-60 min before the first meal of the day for optimal efficacy (H+/K+-ATPase is most active when parietal cells are stimulated) - Goodman & Gilman's, 15th Ed.
• CYP2C19 polymorphisms affect first-generation PPI efficacy (omeprazole, lansoprazole, pantoprazole). Rabeprazole and esomeprazole are less affected by CYP2C19 genotype. P-CABs sidestep this issue entirely. - Yamada's Textbook of Gastroenterology, 7th Ed.
• PPIs + clopidogrel: Use caution. Omeprazole (a CYP2C19 inhibitor) reduces clopidogrel antiplatelet efficacy. Pantoprazole or rabeprazole are preferred if a PPI is needed alongside clopidogrel. - Goodman & Gilman's
• Rebound hypersecretion after PPI withdrawal is mediated by upregulation of H+/K+-ATPase during therapy. Gradual tapering is preferred over abrupt cessation.

Summary Table: When to Use What

• ASGE GERD Guideline 2025 - PMID 39692638
• ACG H. pylori Guideline 2024 - PMID 39626064
• SCCM/ASHP Stress Ulcer Prophylaxis Guideline 2024 - PMID 39007578
• AGA P-CAB Clinical Practice Update 2024 - PMID 39269391
• ISG PPI Stewardship Guidelines 2023 - PMID 37698821
• Goodman & Gilman's Pharmacological Basis of Therapeutics, 14th Ed. - Chapter 53
• Yamada's Textbook of Gastroenterology, 7th Ed. - PPI pharmacology

Dopamine-Prolactin Interaction and Regulation

1. The Core Concept: Dopamine as the Prolactin Inhibitory Factor (PIF)

"Unlike other hormones secreted by the hypothalamus, which stimulate the release of pituitary hormones, dopamine released from the hypothalamus actually inhibits the release of prolactin from lactotrophic cells of the anterior pituitary." - Adams and Victor's Principles of Neurology, 12th Ed.

2. Anatomy of the Pathway: Tuberoinfundibular Dopaminergic (TIDA) Neurons

Arcuate nucleus (mediobasal hypothalamus)
         |
         ↓  (axon projection)
External zone of the MEDIAN EMINENCE
         |
         ↓  (dopamine secreted into portal blood)
HYPOPHYSEAL PORTAL VASCULATURE
         |
         ↓  (carried to anterior pituitary)
D2 RECEPTORS on LACTOTROPHS (anterior pituitary)
         |
         ↓  (inhibition of prolactin synthesis + secretion)
↓ PROLACTIN RELEASE

• Cell bodies in the arcuate nucleus of the mediobasal hypothalamus
• Project to the external zone of the median eminence (NOT the posterior pituitary)
• Dopamine released there enters the hypophyseal portal capillaries - a short, specialized portal blood system connecting hypothalamus to anterior pituitary
• Dopamine binds D2 receptors on lactotrophs → inhibits prolactin release

3. Molecular Mechanism at the Lactotroph

• D2 receptor is a Gi-coupled GPCR
• Activation → inhibition of adenylyl cyclase → ↓cAMP → ↓protein kinase A activity → reduced prolactin gene transcription and exocytosis
• Both D2L (long isoform) and D2S (short isoform) are expressed on lactotrophs

4. Prolactin's Feedback Loop on Dopamine

• Elevated prolactin → stimulates TIDA neurons in the arcuate nucleus → more dopamine released → suppresses its own secretion
• This is mediated through prolactin receptors (PRL-R) expressed on TIDA neurons
• It explains why prolactin levels are normally tightly regulated

"Prolactin also inhibits its secretion using a short-loop feedback circuit to the hypothalamus." - Kaplan & Sadock's Synopsis of Psychiatry

5. Factors That Regulate Prolactin Secretion

Inhibitors of Prolactin (reduce prolactin)

Stimulators of Prolactin (raise prolactin)

From Goldman-Cecil Medicine, 26th Ed: "Thyrotropin-releasing hormone (TRH) and vasoactive intestinal peptide (VIP) also stimulate the release of prolactin, so when hypothyroidism increases TRH release, it causes hyperprolactinemia."

6. Normal Prolactin Values and Physiological Range

Values >250 µg/L almost always indicate a macroprolactinoma - Harrison's Principles of Internal Medicine, 22nd Ed (2025)

7. Causes of Hyperprolactinemia: The "Dopamine Disruption" Framework

1. Blocking dopamine's action on the lactotroph
2. Reducing dopamine delivery to the pituitary
3. Autonomous prolactin production by a tumor

8. Clinical Consequences of Disrupting Dopamine-Prolactin Balance

Hyperprolactinemia Effects

• Galactorrhea - inappropriate lactation (men and women)
• Amenorrhea / oligomenorrhea - PRL suppresses GnRH pulsatility → ↓LH/FSH → anovulation
• Infertility (women and men)
• Hypogonadism - ↓testosterone in men → loss of libido, erectile dysfunction
• Osteoporosis - via hypogonadism, especially in postmenopausal women not on estrogen
• Gynecomastia (men)
• Psychiatric symptoms - depression, anxiety, decreased libido, stress intolerance (PMID: 38396659)

Connection to Antipsychotic Side Effects

9. Therapeutic Applications: Restoring Dopamine Inhibition

Dopamine Agonists (D2 agonists)

• Microprolactinomas: first-line treatment; drug may be withdrawn after 2 years if normoprolactinemia achieved and tumor significantly reduced
• Macroprolactinomas: first-line even for large tumors; cabergoline can achieve substantial tumor shrinkage
• Drug-induced hyperprolactinemia: discontinue offending drug if possible; if antipsychotic cannot be stopped, add cabergoline with caution (may worsen psychosis)
• Hypothyroid-induced: thyroid hormone replacement resolves hyperprolactinemia

10. Summary Diagram (Conceptual)

STRESS / SUCKLING / ESTROGEN / TRH / VIP / SEROTONIN
         ↓ (stimulate)
HYPOTHALAMUS
  - TIDA neurons (arcuate nucleus)
  - Release DOPAMINE into portal blood
         ↓ (inhibit)  ← PRL short-loop feedback also stimulates TIDA
ANTERIOR PITUITARY LACTOTROPH
  - D2 receptor (Gi) → ↓ cAMP → ↓ PRL
  - 5HT2A receptor → ↑ PRL (reciprocal)
         ↓
PROLACTIN secreted into circulation
         ↓
TARGET ORGANS: Mammary glands, gonads, behavior, immune cells

• D2 blockers (antipsychotics, antiemetics) → ↑ PRL
• Stalk compression → ↑ PRL (dopamine can't reach pituitary)
• Prolactinoma → autonomous ↑↑ PRL
• Treatment: D2 agonists (cabergoline/bromocriptine) → ↓ PRL

• Adams and Victor's Principles of Neurology, 12th Ed. - Prolactin Inhibition chapter
• Stahl's Essential Psychopharmacology, Neuroscientific Basis - TIDA pathway and D2 pharmacology
• Kaplan & Sadock's Synopsis of Psychiatry - Prolactin as index of dopamine activity
• Harrison's Principles of Internal Medicine, 22nd Ed (2025) - Hyperprolactinemia and Prolactinoma
• Goldman-Cecil Medicine, 26th Ed. - Causes table and regulation
• Qi-Lytle X et al. "Current Review of the Function and Regulation of Tuberoinfundibular Dopamine Neurons." IJMS 2024 (PMID: 38203281)
• Szukiewicz D. "Current Insights in Prolactin Signaling and Ovulatory Function." IJMS 2024 (PMID: 38396659)